LeMaitre Q3 2026 Financial Results
Key Highlights
- ➤Q3 sales $68.0mm, up 11% year over year and 12% organically
- ➤Q3 adjusted EPS $0.65, up 5% year over year
- ➤FY 2026 sales midpoint $275.8mm, up 11% year over year
- ➤B. Braun vascular asset acquisition closed for $19.2mm in October
- ➤Quarterly dividend raised to $0.25 per share, payable December 3
Expert Statements
George LeMaitre, Chairman and CEO of LeMaitre Vascular
“We expect 2026 to be another year of healthy sales (+11%) and EPS growth (+18%). Biologics continue to drive sales due to Artegraft’s international launch and the continued growth of RestoreFlow Allografts. The acquired B. Braun products will strengthen our core vascular portfolio while leveraging our expanding 31-country sales force.”
BURLINGTON, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q3 2026 results, announced a quarterly dividend of $0.25/share, and provided guidance.
Q3 2026: * Sales $68.0mm, +11% (+12% organic) vs. Q3 2025 * Gross margin 71.7% (-360bps, +90 bps vs. adjusted) * Op. expenses $31.0mm (+21%, +18% vs. adjusted) * Op. income $17.7mm (-13%, +5% vs. adjusted) * Op. margin 26% * EPS $0.65 (-14%, +5% vs. adjusted) * Cash up $13.5mm sequentially to $390mm at 9/30/2026 Grafts (+20%) and shunts (+14%) drove Q3 growth. Artegraft sales increased 18%. EMEA sales increased by 18%, Americas 9%, and APAC 5%. 12% organic growth was comprised of 7% price and 5% units.
Get started
Create a free account to read the full story.